• Home
  • NEW DAY MEDICINE
  • 3 (53) 2023
  • 47 -3 (53) 2023 — Sharipov A.M., Alimov A.A. — DIAGNOSTIC VALUE OF NATRIURETIC PEPTIDE IN HEART FAILURE IN CHILDREN WITH CONGENITAL HEART DEFECTS

47 -3 (53) 2023 — Sharipov A.M., Alimov A.A. — DIAGNOSTIC VALUE OF NATRIURETIC PEPTIDE IN HEART FAILURE IN CHILDREN WITH CONGENITAL HEART DEFECTS

DIAGNOSTIC VALUE OF NATRIURETIC PEPTIDE IN HEART FAILURE IN CHILDREN WITH CONGENITAL HEART DEFECTS

Sharipov A.M., Tashkent Pediatric Medical Institute. National Children’s Medical Center. Tashkent. Republic of Uzbekistan

Alimov A.A., Tashkent Pediatric Medical Institute. National Children’s Medical Center. Tashkent. Republic of Uzbekistan

Usmanov R.R., Tashkent Pediatric Medical Institute. National Children’s Medical Center. Tashkent. Republic of Uzbekistan

Rasulov A.A., Tashkent Pediatric Medical Institute. National Children’s Medical Center. Tashkent. Republic of Uzbekistan

Shorakhmetov Sh.Sh. Tashkent Pediatric Medical Institute. National Children’s Medical Center. Tashkent. Republic of Uzbekistan

Resume

The aim of the study was to study the clinical and diagnostic significance of natriuretic peptide (BNP) in heart failure (HF) in children with congenital heart defects.

Methods.  The study included 24 children under 3 years of age with HF. All patients had HF secondary to congenital heart disease and clinical data, echocardiographic parameters were collected. A comparative analysis of the data indicating significant changes in BNP with characteristic changes on the echocardiogram characterizing the signs of heart failure in children was carried out.

Study results: analysis of NT-proBNP values and type of heart disease associated with HF. In our cohort, median NT-proBNP was highest in patients with cyanotic heart disease (248.0 fmol/ml), followed by patients with dilated cardiomyopathy (193.3 fmol/ml). The lowest median value of NT-proBNP was recorded in patients with acyano- tic heart disease.

Conclusion. In patients with HF, BNP and echocardiography can provide diagnostic and prognostic information. The highest BNP values were reported in patients with lower LVEF, but were not statistically significant. The combination of all these data may offer the best tools for optimizing the treatment of heart failure in children.

Keywords: natriuretic peptide, heart failure, congenital heart disease, echocardiography.

First page

267

Last page

271

For citation: Sharipov A.M., Alimov A.A., Usmanov R.R., Rasulov A.A., Shorakhmetov Sh.Sh. – DIAGNOSTIC VALUE OF NATRIURETIC PEPTIDE IN HEART FAILURE IN CHILDREN WITH CONGENITAL HEART DEFECTS //New Day in Medicine 3(53)2023 267-271 https://goo.su/cF8P9u3

LIST OF REFERENCES:

  1. Андреев Д.А., Батищев П.Н. Некоторые аспекты практического использования мозгового натрийуретического пептида в диагностических целях. // Бюллетень НЦССХ им. А.Н.Бакулева РАМН 2004;3:146-155.
  2. Prontera C., Zucchelli G.C., Vittorini S., Storti S., Emdin M., Clerico A. Comparison between analytical performances of polyclonal and monoclonal electrochemiluminescence immunoassays for NT-proBNP. // Clin Chim Acta 2009;400:70-73.
  3. Ross R.D., Bollinger R.O., Pinsky W.W. Grading the severity of congestive heart failure in infants. // Pediatr Cardiol 1992;13:72-75.
  4. Bobillo-Perez S, Girona-Alarcon M, Corniero P, Sole-Ribalta A, Balaguer M, Esteban E, Valls A, Jordan I, Cambra FJ. Pro-atrial natriuretic peptide and proadrenomedullin before cardiac surgery in children. Can we predict the future? PLoS One. 2020 Jul 23;15(7):e0236377. doi: 10.1371/journal.pone.0236377. PMID:32702064; PMCID: PMC7377469.
  5. Rakesh K Singh, TP Singh. Heart failure in children: Management. 2019 June.
  6. Ploegstra MJ, Roofthooft MT, Douwes JM, Bartelds B, Elzenga NJ, van de Weerd D, Hillege HL, Berger RM. Echocardiography in pediatric pulmonary arterial hypertension: early study on assessing disease severity and predicting outcome. // Circ Cardiovasc Imaging. 2014 Dec 31;8(1):e000878. doi: 10.1161/CIRCIMAGING.113.000878. PMID: 25552488.
  7. Ratnasamy C., Kinnamon D.D., Lipshultz S.E., Rusconi P. Associations between neurohormonal and inflammatory activation and heart failure in children. // Am Heart J 2008;155:527-533.
  8. Arques S. Contribution of natriuretic peptide testing and Doppler echocardiography at bedside to the diagnosis of acute heart failure. A practical overview. // Minerva Cardioangiol 2012;60:385-394.
  9. Cantinotti M., Clerico A., Murzi M., Vittorini S., Emdin M. Clinical relevance of measurement of brain natriuretic peptide and N-terminal pro-brain natriuretic peptide in pediatric cardiology. // Clin Chim Acta. 2008;390:12-22.
  10. Johns M.C., Stephenson C. Amino-Terminal Pro–B-Type Natriuretic Peptide Testing in Neonatal and Pediatric Patients. // Am J Cardiol 2008;101:76-81.
  11. Lowenthal A., Camacho B.V., Lowenthal S., Natal-Hernandez L., Liszewski W., Hills N.K., et al. Usefulness of B-type natriuretic peptide and N- terminal pro-B-type natriuretic peptide as biomarkers for heart failure in young children with single ventricle congenital heart disease. // Am J Cardiol 2012;109:866-872.
  12. Santhanakrishnan R., Chong J.P., Ng T.P., Ling L.H., Sim D., Leong K.T., et al. Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction. // Eur J Heart Fail. 2012:14:1338-1347.
  13. Niethammer M., Sieber M., Von Haehling S., Anker S.D., Munzel T., Horstick G., et al. Inflammatory pathways in patients with heart failure and preserved ejection fraction. // Int J Cardiol 2008;129:111–117.
  14. De Denus S., Lavoie J., Ducharme A., O’meara E., Racine N., Sirois M.G., et al. Differences in biomarkers in patients with heart failure with a reduced vs a preserved left ventricular ejection fraction. // Can J Cardiol 2012;28:62-68.

file

download